EA202190532A1 - Ингибиторы аргиназы и способы их применения - Google Patents

Ингибиторы аргиназы и способы их применения

Info

Publication number
EA202190532A1
EA202190532A1 EA202190532A EA202190532A EA202190532A1 EA 202190532 A1 EA202190532 A1 EA 202190532A1 EA 202190532 A EA202190532 A EA 202190532A EA 202190532 A EA202190532 A EA 202190532A EA 202190532 A1 EA202190532 A1 EA 202190532A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
application
arginase inhibitors
boraspiro
dodecan
Prior art date
Application number
EA202190532A
Other languages
English (en)
Russian (ru)
Inventor
Дэдун У
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA202190532A1 publication Critical patent/EA202190532A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA202190532A 2018-08-22 2019-08-21 Ингибиторы аргиназы и способы их применения EA202190532A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862721113P 2018-08-22 2018-08-22
PCT/EP2019/072341 WO2020038983A1 (en) 2018-08-22 2019-08-21 Arginase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
EA202190532A1 true EA202190532A1 (ru) 2021-07-08

Family

ID=67742403

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190532A EA202190532A1 (ru) 2018-08-22 2019-08-21 Ингибиторы аргиназы и способы их применения

Country Status (25)

Country Link
US (1) US11952392B2 (cg-RX-API-DMAC7.html)
EP (2) EP4371614A3 (cg-RX-API-DMAC7.html)
JP (1) JP7441210B2 (cg-RX-API-DMAC7.html)
KR (1) KR102668252B1 (cg-RX-API-DMAC7.html)
CN (1) CN112584900B (cg-RX-API-DMAC7.html)
AU (1) AU2019323663B2 (cg-RX-API-DMAC7.html)
CA (1) CA3109100A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000430A1 (cg-RX-API-DMAC7.html)
DK (1) DK3840837T3 (cg-RX-API-DMAC7.html)
EA (1) EA202190532A1 (cg-RX-API-DMAC7.html)
ES (1) ES2980252T3 (cg-RX-API-DMAC7.html)
FI (1) FI3840837T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240694T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066903T2 (cg-RX-API-DMAC7.html)
IL (1) IL280924B2 (cg-RX-API-DMAC7.html)
LT (1) LT3840837T (cg-RX-API-DMAC7.html)
MA (1) MA53427B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021002042A (cg-RX-API-DMAC7.html)
PL (1) PL3840837T3 (cg-RX-API-DMAC7.html)
PT (1) PT3840837T (cg-RX-API-DMAC7.html)
RS (1) RS65608B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101618PA (cg-RX-API-DMAC7.html)
SI (1) SI3840837T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400221T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020038983A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
MY206577A (en) * 2019-02-08 2024-12-24 Astrazeneca Ab Arginase inhibitors and methods of use thereof
EP4239652A4 (en) 2020-12-25 2024-06-05 Sumitomo Riko Company Limited Electrically conductive composition, sheet-form flexible electrode using same, and method for producing said electrode

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2560978B1 (en) 2010-04-22 2019-01-30 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
AU2016281620B2 (en) * 2015-06-23 2021-07-22 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
US11291674B2 (en) * 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
WO2018119440A1 (en) 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
SG11202007739XA (en) 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
US12215116B2 (en) 2018-03-13 2025-02-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
WO2019205979A1 (zh) 2018-04-27 2019-10-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途

Also Published As

Publication number Publication date
EP3840837B1 (en) 2024-03-20
SMT202400221T1 (it) 2024-07-09
JP7441210B2 (ja) 2024-02-29
CA3109100A1 (en) 2020-02-27
EP4371614A2 (en) 2024-05-22
KR102668252B1 (ko) 2024-05-21
US20210332068A1 (en) 2021-10-28
PL3840837T3 (pl) 2024-08-19
MA53427B1 (fr) 2024-06-28
MX2021002042A (es) 2021-04-28
WO2020038983A1 (en) 2020-02-27
HRP20240694T1 (hr) 2024-08-16
KR20210049120A (ko) 2021-05-04
US11952392B2 (en) 2024-04-09
RS65608B1 (sr) 2024-07-31
CN112584900B (zh) 2025-07-15
IL280924B2 (en) 2024-10-01
HUE066903T2 (hu) 2024-09-28
IL280924B1 (en) 2024-06-01
SI3840837T1 (sl) 2024-07-31
EP3840837A1 (en) 2021-06-30
MA53427A (fr) 2021-12-01
DK3840837T3 (da) 2024-06-10
JP2021535111A (ja) 2021-12-16
AU2019323663B2 (en) 2022-07-14
IL280924A (en) 2021-04-29
SG11202101618PA (en) 2021-03-30
ES2980252T3 (es) 2024-09-30
LT3840837T (lt) 2024-06-10
AU2019323663A1 (en) 2021-04-08
FI3840837T3 (fi) 2024-06-03
EP4371614A3 (en) 2025-09-24
CL2021000430A1 (es) 2021-09-03
PT3840837T (pt) 2024-06-14
CN112584900A (zh) 2021-03-30

Similar Documents

Publication Publication Date Title
JOP20220130A1 (ar) مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم
MX2018010983A (es) Derivado de 3-desoxi y composiciones farmaceuticas del mismo.
EA201792214A1 (ru) Соединения замещенного хиназолина
CL2021000430A1 (es) Inhibidores de arginasa y sus métodos de uso
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
EA202191239A1 (ru) Соединения и их применение для лечения дефицита 1-антитрипсина
MX380928B (es) Inhibidores de kras g12c.
EA201890771A1 (ru) Соли и твердые формы монобактамного антибиотика
CY1123728T1 (el) (2r,4r)-5-(5'-χλωρο-2'-φθοροδιφαινυλ-4-υλ) -2-υδροξυ-4- [(5-μεθυλοξαζολο-2-καρβονυλ) αμινο] πεντανοϊκο οξυ
MX394624B (es) Inhibidores selectivos hdac6, métodos de preparación y aplicación de los mismos.
EA201791696A1 (ru) Композиция для лечения веноокклюзионной болезни печени
EP4129298C0 (en) Pharmaceutical composition compound for the treatment of a fibrotic disease
MX2020008929A (es) Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmaceutico.
EA202191192A1 (ru) Кристаллические соли ингибитора плазменного калликреина
EA201890412A1 (ru) АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ
MX392870B (es) Formas cristalinas de tebipenem pivoxil, composiciones que incluyen a las mismas, metodos de fabricacion, y metodos de utilizacion.
MX2021009796A (es) Inhibidores selectivos de la proteina arginina metiltransferasa 5 (prmt5).
EA201991570A1 (ru) Амидные соединения и их применение
EA202090424A1 (ru) Бициклические ингибиторы гистондеацетилазы
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
EA201890896A1 (ru) Твердый препарат для перорального применения, содержащий аморфный солифенацин, и способ его получения
EA201892532A1 (ru) Пиримидин-2-иламино-1н-пиразолы в качестве ингибиторов lrrk2 для применения при лечении нейродегенеративных заболеваний
TW201713630A (en) Substituted quinazoline compounds and methods of use thereof